Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) just unveiled an update.
ResMed Inc. has reported changes in the beneficial ownership of its securities, as disclosed in a recent filing. Brett Sandercock, the company’s Chief Financial Officer, executed transactions involving the acquisition and disposal of ResMed common stock under a pre-established Rule 10b5-1 trading plan. These transactions reflect ongoing strategic financial management and compliance with regulatory requirements, potentially impacting investor perceptions and market dynamics concerning ResMed’s stock.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$48.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of products related to sleep disorders and respiratory care. The company is known for its innovative solutions in sleep apnea treatment and offers a range of devices and cloud-connected software applications aimed at improving patient outcomes and enhancing the quality of life for individuals with chronic respiratory conditions.
Average Trading Volume: 1,049,105
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$62.56B
See more data about RMD stock on TipRanks’ Stock Analysis page.